{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:46:21Z","timestamp":1785797181686,"version":"3.56.0"},"reference-count":96,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background: The role and optimal sequencing of radium-223 in the treatment of metastatic castration-resistant prostate cancer (mCRPC) remain debated. In Europe, radium-223 is restricted to third line treatment or later for chemotherapy-eligible men, although studies suggest greater benefit with earlier use. In this nationwide, population-based study, we investigated radium-223 use in Sweden and analyzed the association between line of treatment and overall survival.\nMethods: Men with mCRPC who started radium-223 in 2014-2020 were identified in national registers. The Kaplan-Meier method was used to estimate survival. The association between line of treatment and survival was analyzed with Cox regression and presented as adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs). A subgroup with at least three mCRPC treatment lines was similarly analyzed.\nResults: 1,133 men were included. Median overall survival was 13.9 months (95% CI 13.0-14.5). Later line of radium-223 treatment was associated with shorter survival; with first line as reference, aHR for death for second line was 1.34 (95% CI 1.12-1.59) and for third line 1.55 (1.29-1.87). The opposite was observed for 596 men with at least three lines of mCRPC treatment: aHR for second line was 0.80 (0.59-1.08) and for third line 0.78 (0.59-1.03).\nInterpretation: Survival after start of radium-223 in Sweden was comparable to pivotal trials, suggesting effective use. Our overall results do not suggest a better effect of radium-223 in first versus later mCRPC treatment lines but rather emphasize the value of a randomized controlled trial to more definitely determine the optimal timing of radium-223 treatment.<\/jats:p>","DOI":"10.2340\/1651-226x.2025.43794","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T11:04:49Z","timestamp":1760353489000},"page":"1391-1403","source":"Crossref","is-referenced-by-count":2,"title":["Radium-223 use and survival by line of treatment in metastatic castration-resistant prostate cancer: a nationwide population-based register study"],"prefix":"10.2340","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8554-1046","authenticated-orcid":false,"given":"Charlotte","family":"Alverbratt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Sandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Kolmb\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7181-7083","authenticated-orcid":false,"given":"Hans","family":"Garmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9198-9445","authenticated-orcid":false,"given":"Ola","family":"Bratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8612-9814","authenticated-orcid":false,"given":"Ingela","family":"Franck Lissbrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"129484","doi-asserted-by":"crossref","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213\u201323.","DOI":"10.1056\/NEJMoa1213755"},{"key":"129485","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1213755","DOI":"10.1056\/NEJMoa1213755"},{"key":"129486","doi-asserted-by":"crossref","unstructured":"van der Doelen MJ, Mehra N, Hermsen R, Janssen MJR, Gerritsen WR, van Oort IM. Patient selection for radium-223 therapy in patients with bone metastatic castration-resistant prostate cancer: new recommendations and future perspectives. Clin Genitourin Cancer. 2019;17(2):79\u201387.","DOI":"10.1016\/j.clgc.2018.11.008"},{"key":"129487","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clgc.2018.11.008","DOI":"10.1016\/j.clgc.2018.11.008"},{"key":"129488","doi-asserted-by":"crossref","unstructured":"Heinrich D, Bektic J, Bergman AM, Caffo O, Cathomas R, Chi KN, et al. The contemporary use of radium-223 in metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2018;16(1):e223\u201331.","DOI":"10.1016\/j.clgc.2017.08.020"},{"key":"129489","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clgc.2017.08.020","DOI":"10.1016\/j.clgc.2017.08.020"},{"key":"129490","doi-asserted-by":"crossref","unstructured":"Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin M-E, Kungel TM, et al. Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update. J Clin Oncol. 2025;43(20):2311\u201334.","DOI":"10.1200\/JCO-25-00007"},{"key":"129491","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO-25-00007","DOI":"10.1200\/JCO-25-00007"},{"key":"129492","doi-asserted-by":"crossref","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;86(2):164\u201382.","DOI":"10.1016\/j.eururo.2024.04.010"},{"key":"129493","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010","DOI":"10.1016\/j.eururo.2024.04.010"},{"key":"129494","doi-asserted-by":"crossref","unstructured":"Shore N, Carles J, McDermott R, Agarwal N, Tombal B. Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer. Front Med (Lausanne). 2024;11:1460212.","DOI":"10.3389\/fmed.2024.1460212"},{"key":"129495","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fmed.2024.1460212","DOI":"10.3389\/fmed.2024.1460212"},{"key":"129496","doi-asserted-by":"crossref","unstructured":"Morris MJ, Wit RD, Vogelzang NJ, Tagawa ST, Higano CS, Hamberg P. A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA. J Clin Oncol. 2021;39(15_Suppl):TPS5091.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5091"},{"key":"129497","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS5091","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5091"},{"key":"129498","doi-asserted-by":"crossref","unstructured":"Fizazi K, Alba AGd, Mustafa \u00d6, Skoneczna IA, Krissel H, Uema D, et al. Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study. J Clin Oncol. 2021;39(15_suppl):TPS5093.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5093"},{"key":"129499","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS5093","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5093"},{"key":"129500","doi-asserted-by":"crossref","unstructured":"Gillessen S, Choudhury A, Saad F, Gallardo E, Soares A, Loriot Y, et al. LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): first results of EORTC-GUCG 1333\/PEACE-3. Ann Oncol. 2024;35:S1254.","DOI":"10.1016\/j.annonc.2024.08.2307"},{"key":"129501","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2307","DOI":"10.1016\/j.annonc.2024.08.2307"},{"key":"129502","doi-asserted-by":"crossref","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence \u2013 what is it and what can it tell us? N Engl J Med. 2016;375(23):2293\u20137.","DOI":"10.1056\/NEJMsb1609216"},{"key":"129503","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMsb1609216","DOI":"10.1056\/NEJMsb1609216"},{"key":"129504","doi-asserted-by":"crossref","unstructured":"Hoskin P, Sartor O, O\u2019Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397\u2013406.","DOI":"10.1016\/S1470-2045(14)70474-7"},{"key":"129505","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(14)70474-7","DOI":"10.1016\/S1470-2045(14)70474-7"},{"key":"129506","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan JM, McKay RR, Rahbar K, Fizazi K, George DJ, Tombal B, et al. Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer. Front Med (Lausanne). 2022;9:fmed-09-1070392.","DOI":"10.3389\/fmed.2022.1070392"},{"key":"129507","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fmed.2022.1070392","DOI":"10.3389\/fmed.2022.1070392"},{"key":"129508","doi-asserted-by":"crossref","unstructured":"George DJ, Agarwal N, Sartor O, Sternberg CN, Tombal B, Saad F, et al. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). Prostate Cancer Prostatic Dis. 2022;25(2):306\u201313.","DOI":"10.1038\/s41391-021-00488-0"},{"key":"129509","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41391-021-00488-0","DOI":"10.1038\/s41391-021-00488-0"},{"key":"129510","unstructured":"EMA restricts the use of prostate cancer medicine Xofigo [Internet]. London: European Medicines Agency; 2018 [press release]. [Cited date: 15 April 2024] Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/xofigo"},{"key":"129511","doi-asserted-by":"crossref","unstructured":"Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):408\u201319.","DOI":"10.1016\/S1470-2045(18)30860-X"},{"key":"129512","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(18)30860-X","DOI":"10.1016\/S1470-2045(18)30860-X"},{"key":"129513","doi-asserted-by":"crossref","unstructured":"Kitajima K, Igeta M, Kuyama J, Kawahara T, Suga T, Otani T, et al. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) trial. Eur J Nucl Med Mol Imaging. 2023;50(5):1487\u201398.","DOI":"10.1007\/s00259-022-06082-3"},{"key":"129514","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00259-022-06082-3","DOI":"10.1007\/s00259-022-06082-3"},{"key":"129515","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan JM, Heinrich D, James ND, Nilsson S, Ost P, Parker CC, et al. The case against the European Medicines Agency\u2019s change to the label for radium-223 for the treatment of metastatic castration-resistant prostate cancer. Eur Urol. 2019;75(3):e51\u20132.","DOI":"10.1016\/j.eururo.2018.11.003"},{"key":"129516","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2018.11.003","DOI":"10.1016\/j.eururo.2018.11.003"},{"key":"129517","doi-asserted-by":"crossref","unstructured":"Van den Wyngaert T, Tombal B. The changing role of radium-223 in metastatic castrate-resistant prostate cancer: has the EMA missed the mark with revising the label? Q J Nucl Med Mol Imaging. 2019;63(2):170\u201382.","DOI":"10.23736\/S1824-4785.19.03205-9"},{"key":"129518","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.23736\/S1824-4785.19.03205-9","DOI":"10.23736\/S1824-4785.19.03205-9"},{"key":"129519","doi-asserted-by":"crossref","unstructured":"Heidenreich A, Gillessen S, Heinrich D, Keizman D, O\u2019Sullivan JM, Carles J, et al. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. BMC Cancer. 2019;19(1):12.","DOI":"10.1186\/s12885-018-5203-y"},{"key":"129520","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12885-018-5203-y","DOI":"10.1186\/s12885-018-5203-y"},{"key":"129521","doi-asserted-by":"crossref","unstructured":"Jarvis P, Ho A, Sundram F. Radium-223 therapy for metastatic castration-resistant prostate cancer: survival benefit when used earlier in the treatment pathway. Nucl Med Commun. 2021;42(3):332\u20136.","DOI":"10.1097\/MNM.0000000000001325"},{"key":"129522","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/MNM.0000000000001325","DOI":"10.1097\/MNM.0000000000001325"},{"key":"129523","doi-asserted-by":"crossref","unstructured":"Kuppen MC, Westgeest HM, van der Doelen MJ, van den Eertwegh AJ, Coenen JL, Aben KK, et al. Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Future Oncol. 2020;16(19):1371\u201384.","DOI":"10.2217\/fon-2020-0039"},{"key":"129524","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2217\/fon-2020-0039","DOI":"10.2217\/fon-2020-0039"},{"key":"129525","doi-asserted-by":"crossref","unstructured":"Shariftabrizi A, Kothari S, George S, Attwood K, Levine E, Lamonica D. Optimization of radium-223 treatment of castration-resistant prostate cancer based on the burden of skeletal metastasis and clinical parameters. Oncologist. 2023;28(3):246\u201351.","DOI":"10.1093\/oncolo\/oyac245"},{"key":"129526","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/oncolo\/oyac245","DOI":"10.1093\/oncolo\/oyac245"},{"key":"129527","doi-asserted-by":"crossref","unstructured":"Pezaro C, Omlin A, Lorente D, Rodrigues DN, Ferraldeschi R, Bianchini D, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014;65(2):270\u20133.","DOI":"10.1016\/j.eururo.2013.10.055"},{"key":"129528","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2013.10.055","DOI":"10.1016\/j.eururo.2013.10.055"},{"key":"129529","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan JM, Abramowitz E, Sierra-Scacalossi L. Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary. Future Oncol. 2023;19(15):1021\u20138.","DOI":"10.2217\/fon-2022-1296"},{"key":"129530","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2217\/fon-2022-1296","DOI":"10.2217\/fon-2022-1296"},{"key":"129531","doi-asserted-by":"crossref","unstructured":"Lozano R, Almagro E, Castro E. Relevance of radium-223 in hospital clinical practice from a medical oncologist point of view. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2019;38(2):106\u201311.","DOI":"10.1016\/j.remnie.2019.02.001"},{"key":"129532","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.remnie.2019.02.001","DOI":"10.1016\/j.remnie.2019.02.001"},{"key":"129533","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Veiga F, \u00c1lvarez-Ossorio JL, Carballido-Rodr\u00edguez J, Ju\u00e1rez-Soto A, Rodr\u00edguez-Antol\u00edn A, Cozar-Olmo JM. Radium-223 for the treatment of metastatic castration-resistant prostate cancer: a window of opportunity. Actas Urol Esp (Engl Ed). 2018;42(10):616\u201324.","DOI":"10.1016\/j.acuroe.2018.10.005"},{"key":"129534","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.acuro.2018.05.004","DOI":"10.1016\/j.acuro.2018.05.004"},{"key":"129535","doi-asserted-by":"crossref","unstructured":"Maruzzo M, Basso U, Borsatti E, Evangelista L, Alongi F, Caffo O, et al. Results from a large, multicenter, retrospective analysis on radium223 use in metastatic castration-resistant prostate cancer (mCRPC) in the Triveneto Italian Region. Clin Genitourin Cancer. 2019;17(1):e187\u201394.","DOI":"10.1016\/j.clgc.2018.10.013"},{"key":"129536","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clgc.2018.10.013","DOI":"10.1016\/j.clgc.2018.10.013"},{"key":"129537","doi-asserted-by":"crossref","unstructured":"Caffo O, Frantellizzi V, Tucci M, Galli L, Monari F, Baldari S, et al. Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223. Eur J Nucl Med Mol Imaging. 2020;47(11):2633\u20138.","DOI":"10.1007\/s00259-020-04796-w"},{"key":"129538","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00259-020-04796-w","DOI":"10.1007\/s00259-020-04796-w"},{"key":"129539","doi-asserted-by":"crossref","unstructured":"Stattin P, Westerberg M, Lissbrant IF, Eriksson MH, Kjellman A, Ull\u00e9n A, et al. Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden. Clin Genitourin Cancer. 2023;21(1):107.e1\u20139.","DOI":"10.1016\/j.clgc.2022.09.002"},{"key":"129540","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00259-020-04796-w","DOI":"10.1007\/s00259-020-04796-w"},{"key":"129541","doi-asserted-by":"crossref","unstructured":"Van Hemelrijck M, Wigertz A, Sandin F, Garmo H, Hellstrom K, Fransson P, et al. Cohort profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol. 2013;42(4):956\u201367.","DOI":"10.1093\/ije\/dys068"},{"key":"129542","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/ije\/dys068","DOI":"10.1093\/ije\/dys068"},{"key":"129543","doi-asserted-by":"crossref","unstructured":"Franck Lissbrant I, Hj\u00e4lm Eriksson M, Lambe M, T\u00f6rnblom M, Stattin P. Set-up and preliminary results from the patient-overview prostate cancer. Longitudinal registration of treatment of advanced prostate cancer in the National Prostate Cancer Register of Sweden. Scand J Urol. 2020;54(3):227\u201334.","DOI":"10.1080\/21681805.2020.1756402"},{"key":"129544","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2020.1756402","DOI":"10.1080\/21681805.2020.1756402"},{"key":"129545","doi-asserted-by":"crossref","unstructured":"Fallara G, Alverbratt C, Garmo H, Vikman H, Hjelm Eriksson M, Lissbrant IF, et al. Time on treatment with abiraterone and enzalutamide in the patient-overview prostate cancer in the National Prostate Cancer Register of Sweden. Acta Oncol. 2021;60(12):1589\u201396.","DOI":"10.1080\/0284186X.2021.1978539"},{"key":"129546","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2021.1978539","DOI":"10.1080\/0284186X.2021.1978539"},{"key":"129547","doi-asserted-by":"crossref","unstructured":"Cheng Q, Butler W, Zhou Y, Zhang H, Tang L, Perkinson K, et al. Pre-existing castration-resistant prostate cancer\u2013like cells in primary prostate cancer promote resistance to hormonal therapy. Eur Urol. 2022;81(5):446\u201355.","DOI":"10.1016\/j.eururo.2021.12.039"},{"key":"129548","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2021.12.039","DOI":"10.1016\/j.eururo.2021.12.039"},{"key":"129549","doi-asserted-by":"crossref","unstructured":"Goyal J, Pond GR, Galsky MD, Hendricks R, Small A, Tsao CK, et al. Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer. Urol Oncol. 2014;32(1):36.e27\u201334.","DOI":"10.1016\/j.urolonc.2013.02.015"},{"key":"129550","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.urolonc.2013.02.015","DOI":"10.1016\/j.urolonc.2013.02.015"},{"key":"129551","doi-asserted-by":"crossref","unstructured":"Whitney CA, Howard LE, Freedland SJ, DeHoedt AM, Amling CL, Aronson WJ, et al. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019;22(2):252\u201360.","DOI":"10.1038\/s41391-018-0095-0"},{"key":"129552","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41391-018-0095-0","DOI":"10.1038\/s41391-018-0095-0"},{"key":"129553","doi-asserted-by":"crossref","unstructured":"Zist A, Amir E, Ocana AF, Seruga B. Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel. Radiol Oncol. 2015;49(4):402\u20138.","DOI":"10.1515\/raon-2015-0038"},{"key":"129554","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1515\/raon-2015-0038","DOI":"10.1515\/raon-2015-0038"},{"key":"129555","doi-asserted-by":"crossref","unstructured":"McKay RR, Silver R, Bhak RH, Korves C, Cheng M, Appukkuttan S, et al. Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center. Prostate Cancer Prostatic Dis. 2021;24(1):210\u201319.","DOI":"10.1038\/s41391-020-00271-7"},{"key":"129556","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41391-020-00271-7","DOI":"10.1038\/s41391-020-00271-7"},{"key":"129557","doi-asserted-by":"crossref","unstructured":"Higano CS, George DJ, Shore ND, Sartor O, Miller K, Conti PS, et al. Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer. EClinicalMedicine. 2023;60:101993.","DOI":"10.1016\/j.eclinm.2023.101993"},{"key":"129558","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.101993","DOI":"10.1016\/j.eclinm.2023.101993"},{"key":"129559","doi-asserted-by":"crossref","unstructured":"Hyv\u00e4kk\u00e4 A, K\u00e4\u00e4ri\u00e4inen OS, Utriainen T, L\u00f6yttyniemi E, Mattila K, Reinikainen P, et al. Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: a real-world evidence multicenter study. Cancer Med. 2023;12(4):4064\u201376.","DOI":"10.1002\/cam4.5262"},{"key":"129560","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cam4.5262","DOI":"10.1002\/cam4.5262"},{"key":"129561","doi-asserted-by":"crossref","unstructured":"Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017;28(5):1090\u20137.","DOI":"10.1093\/annonc\/mdx044"},{"key":"129562","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdx044","DOI":"10.1093\/annonc\/mdx044"},{"key":"129563","doi-asserted-by":"crossref","unstructured":"Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17(9):1306\u201316.","DOI":"10.1016\/S1470-2045(16)30173-5"},{"key":"129564","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(16)30173-5","DOI":"10.1016\/S1470-2045(16)30173-5"},{"key":"129565","unstructured":"Peters N, Bambury RM, Power DG, McCarthy L, Lyons C, Kelly P, et al. Radium-223 in the treatment of metastatic castrate-resistant prostate cancer. Ir Med J. 2022;115(2):536."},{"key":"129566","doi-asserted-by":"crossref","unstructured":"Dizdarevic S, Jessop M, Begley P, Main S, Robinson A. (223)Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice. Eur J Nucl Med Mol Imaging. 2018;45(13):2264\u201373.","DOI":"10.1007\/s00259-018-4083-3"},{"key":"129567","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00259-018-4083-3","DOI":"10.1007\/s00259-018-4083-3"},{"key":"129568","doi-asserted-by":"crossref","unstructured":"Parikh S, Murray L, Kenning L, Bottomley D, Din O, Dixit S, et al. Real-world outcomes and factors predicting survival and completion of radium 223 in metastatic castrate-resistant prostate cancer. Clin Oncol. 2018;30(9):548\u201355.","DOI":"10.1016\/j.clon.2018.06.004"},{"key":"129569","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clon.2018.06.004","DOI":"10.1016\/j.clon.2018.06.004"},{"key":"129570","doi-asserted-by":"crossref","unstructured":"Sartor O, Appukkuttan S, Weiss J, Tsao C-K. Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings. Prostate. 2021;81(10):657\u201366.","DOI":"10.1002\/pros.24143"},{"key":"129571","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/pros.24143","DOI":"10.1002\/pros.24143"},{"key":"129572","doi-asserted-by":"crossref","unstructured":"Cheng S, Arciero V, Goldberg H, Tajzler C, Manganaro A, Kozlowski N, et al. Population-based analysis of the use of radium-223 for bone-metastatic castration-resistant prostate cancer in Ontario, and of factors associated with treatment completion and outcome. Cancer Manag Res. 2019;11:9307\u201319.","DOI":"10.2147\/CMAR.S213051"},{"key":"129573","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CMAR.S213051","DOI":"10.2147\/CMAR.S213051"},{"key":"129574","doi-asserted-by":"crossref","unstructured":"Buscombe J, Gillett D, Bird N, Powell A, Heard S, Aloj L. Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases. World J Nucl Med. 2021;20(2):139\u201344.","DOI":"10.4103\/wjnm.WJNM_74_20"},{"key":"129575","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.4103\/wjnm.WJNM_74_20","DOI":"10.4103\/wjnm.WJNM_74_20"},{"key":"129576","doi-asserted-by":"crossref","unstructured":"Miyoshi Y, Tsutsumi S, Yasui M, Kawahara T, Uemura K-i, Hayashi N, et al. A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer. World J Urol. 2021;39(9):3323\u20138.","DOI":"10.1007\/s00345-021-03639-z"},{"key":"129577","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00345-021-03639-z","DOI":"10.1007\/s00345-021-03639-z"},{"key":"129578","doi-asserted-by":"crossref","unstructured":"Dadhania S, Alonzi R, Douglas S, Gogbashian A, Hughes R, Dalili D, et al. Single-centre experience of use of radium 223 with clinical outcomes based on number of cycles and bone marrow toxicity. Anticancer Res. 2018;38(9):5423\u20137.","DOI":"10.21873\/anticanres.12873"},{"key":"129579","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.21873\/anticanres.12873","DOI":"10.21873\/anticanres.12873"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/43794\/51724","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/43794\/51724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T11:05:34Z","timestamp":1760353534000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/43794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":96,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2025.43794","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]}}}